mAb treatment to prevent severe COVID-19

Hillary D. Lum; Bethany Kwan; Allyson Gottsman; Lindsey E. Fish; Misha Huang; Adit Ginde

doi:10.25677/jed89-vjb90

January 1, 2021Open Access

mAb treatment to prevent severe COVID-19

View Full Paper

Ask AI

Bookmark

Share

Key Points

To provide a structured approach for healthcare providers to determine eligibility for monoclonal antibody treatment in patients at risk for severe COVID-19.
Developed a flow-chart for provider use
Focused on patient eligibility criteria
Last updated in fall 2021
Streamlined the decision-making process for providers
Facilitated better identification of eligible patients for treatment

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

A flow-chart guides provider eligibility for COVID-19 monoclonal antibody treatment in Colorado, indicating clinical readiness.

Abstract

This mAb flyer shows a flow-chart created for provider use to determine patient eligibilty for COVID-19 monoclonal anti-body treatment in Colorado. Last updated fall 2021.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lum et al. (2021) studied this question.

synapsesocial.com/papers/69b3abd602a1e69014ccd097 https://doi.org/10.25677/jed89-vjb90

View Full Paper

Ask AI

Bookmark

Share

mAb treatment to prevent severe COVID-19

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

mAb treatment to prevent severe COVID-19

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading